Trial
NCT04570956
Oral Tamoxifen vs. TamGel vs. Control in Women With Atypical Hyperplasia, Lobular Carcinoma In Situ, or Increased Breast Cancer Risk
Phase IITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Mayo Clinic
Collaborators
National Cancer Institute (NCI)
Condition
Breast Atypical Hyperplasia
Intervention
Tamoxifen
Why stopped
grant and funding expired
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2026-01-23